Literature DB >> 14741435

Cannabinoid receptors and T helper cells.

Thomas W Klein1, Cathy Newton, Kellie Larsen, Joe Chou, Izabella Perkins, Lily Lu, Liang Nong, Herman Friedman.   

Abstract

We have reported that injection of marijuana cannabinoids, such as Delta(9)-tetrahydrocannabinol (THC), into mice, followed by infection with Legionella pneumophila (Lp), suppresses the development of cell-mediated immunity T helper 1 (Th1) activity. These effects are accompanied by suppression of interleukin (IL)-12 and interferon (IFN) gamma production and enhancement of IL-4 production suggesting THC-induced T helper cell biasing. In the current report, other T helper cell biasing mechanisms were studied. Mice were injected with THC followed 18 h later by a challenge infection with Lp. Two-hour post-infection, spleens were removed and analyzed for mRNA to either IL-12Rbeta2 or GATA3 gene products. The results showed that THC suppressed IL-12Rbeta2 but increased GATA3. Receptor antagonists for CB1 (SR141716A, SR1) and CB2 (SR144528, SR2) were also injected to analyze the involvement of cannabinoid receptors. It was determined that SR1 attenuated the THC suppression of IL-12Rbeta2, while SR2 attenuated the increase in GATA3 mRNA. These results suggest that THC suppresses Th1 biasing activity such as IL-12Rbeta2 by a CB1 mediated mechanism and enhances the Th2 biasing activity, GATA3, by a CB2 mechanism. This dichotomy of receptor involvement might result from differential expression and/or signaling function of CB1 and CB2 on Th1 and Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741435     DOI: 10.1016/j.jneuroim.2003.10.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

1.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.

Authors:  Régis Roche; Laurence Hoareau; Sandrine Bes-Houtmann; Marie-Paule Gonthier; Christine Laborde; Jean-François Baron; Yacine Haffaf; Maya Cesari; Franck Festy
Journal:  Histochem Cell Biol       Date:  2006-01-04       Impact factor: 4.304

2.  Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1.

Authors:  Austin R Jackson; Venkatesh L Hegde; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

3.  Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.

Authors:  Christine Börner; Michal Smida; Volker Höllt; Burkhart Schraven; Jürgen Kraus
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

4.  Modulation of gut-specific mechanisms by chronic δ(9)-tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis.

Authors:  Patricia E Molina; Angela M Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter J Winsauer; Curtis Vande Stouwe; Robin R McGoey; Matthew W Auten; Lynn LaMotte; Lawrance C Chandra; Leslie L Birke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

Review 5.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

Review 6.  Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Authors:  William E Greineisen; Helen Turner
Journal:  Int Immunopharmacol       Date:  2010-02-25       Impact factor: 4.932

7.  Cannabinoid influence on cytokine profile in multiple sclerosis.

Authors:  S Katona; E Kaminski; H Sanders; J Zajicek
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 8.  Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.

Authors:  B N Dittel
Journal:  Br J Pharmacol       Date:  2007-10-08       Impact factor: 8.739

Review 9.  The peripheral cannabinoid receptor knockout mice: an update.

Authors:  N E Buckley
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 10.  Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.

Authors:  Harold Bays; Carlos A Dujovne
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.